NG-350A is an innovative immunotherapy designed to enhance immune response by targeting primary and metastatic tumor sites in rectal cancer. The FORTRESS trial combines NG-350A with standard ...
Hosted on MSN
Rectal Cancer Vanishes After Immunotherapy Trial, Now Classified as FDA Breakthrough Therapy
A humble yet groundbreaking clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has achieved unprecedented results in the treatment of rectal cancer, marking an incredible milestone in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results